Editorial & Opinion
Attack of the clones: Unveiling subclonal/heterogenous mismatch repair/microsatellite instability status in endometrial cancer.
العنوان: | Attack of the clones: Unveiling subclonal/heterogenous mismatch repair/microsatellite instability status in endometrial cancer. |
---|---|
المؤلفون: | Grither WR; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology and Alvin J. Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA., Hagemann IS; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology and Alvin J. Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA.; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri, USA., Powell MA; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology and Alvin J. Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA., Mullen MM; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology and Alvin J. Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA. |
المصدر: | Cancer [Cancer] 2024 Feb 01; Vol. 130 (3), pp. 339-341. Date of Electronic Publication: 2023 Oct 30. |
نوع المنشور: | Editorial; Comment |
اللغة: | English |
بيانات الدورية: | Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE |
أسماء مطبوعة: | Publication: <2005- >: Hoboken, NJ : Wiley Original Publication: New York [etc.] Published for the American Cancer Society by J. Wiley [etc.] |
مواضيع طبية MeSH: | DNA Mismatch Repair*/genetics , Endometrial Neoplasms*/genetics, Female ; Humans ; Microsatellite Instability ; Biomarkers, Tumor ; Clone Cells/metabolism ; MutL Protein Homolog 1/genetics |
التعليقات: | Comment on: Cancer. 2024 Feb 1;130(3):385-399. (PMID: 37751191) |
References: | McMeekin DS, Tritchler DL, Cohn DE, et al. Clinicopathologic significance of mismatch repair defects in endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol. 2016;34(25):3062-3068. doi:10.1200/jco.2016.67.8722. Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67-73. doi:10.1038/nature12113. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409-413. doi:10.1126/science.aan6733. Mirza MR, Chase DM, Slomovitz BM, et al. Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Med. 2023;388(23):2145-2158. doi:10.1056/nejmoa2216334. O'Malley DM, Bariani GM, Cassier PA, et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study. J Clin Oncol. 2022;40(7):752-761. doi:10.1200/jco.21.01874. Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med. 2023;388(23):2159-2170. doi:10.1056/nejmoa2302312. Makker V, Colombo N, Casado Herraez A, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022;386(5):437-448. doi:10.1056/nejmoa2108330. Engel KB, Moore HM. Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med. 2011;135(5):537-543. doi:10.5858/2010-0702-rair.1. Luchini C, Bibeau F, Ligtenberg MJL, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019;30(8):1232-1243. doi:10.1093/annonc/mdz116. Raffone A, Travaglino A, Cerbone M, et al. Diagnostic accuracy of immunohistochemistry for mismatch repair proteins as surrogate of microsatellite instability molecular testing in endometrial cancer. Pathol Oncol Res. 2020;26(3):1417-1427. doi:10.1007/s12253-020-00811-5. Zhang L. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing. J Mol Diagn. 2008;10(4):301-307. doi:10.2353/jmoldx.2008.080062. Stelloo E, Jansen AML, Osse EM, et al. Practical guidance for mismatch repair-deficiency testing in endometrial cancer. Ann Oncol. 2017;28(1):96-102. doi:10.1093/annonc/mdw542. Esteller M, Levine R, Baylin SB, Ellenson LH, Herman JG. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene. 1998;17(18):2413-2417. doi:10.1038/sj.onc.1202178. Riedinger CJ, Esnakula A, Haight PJ, et al. Characterization of mismatch repair (MMR)/microsatellite instability (MSI)-discordant endometrial cancers. Cancer. 2023;000:000-000. doi:10.1002/cncr.35030. Pai RK, Plesec TP, Abdul-Karim FW, et al. Abrupt loss of MLH1 and PMS2 expression in endometrial carcinoma: molecular and morphologic analysis of 6 cases. Am J Surg Pathol. 2015;39(7):993-999. doi:10.1097/pas.0000000000000415. Watkins JC, Nucci MR, Ritterhouse LL, Howitt BE, Sholl LM. Unusual mismatch repair immunohistochemical patterns in endometrial carcinoma. Am J Surg Pathol. 2016;40(7):909-916. doi:10.1097/pas.0000000000000663. Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn. 2008;10(4):293-300. doi:10.2353/jmoldx.2008.080031. Rakha EA, Chmielik E, Schmitt FC, Tan PH, Quinn CM, Gallagy G. Assessment of predictive biomarkers in breast cancer: challenges and updates. Pathobiology. 2022;89(5):263-277. doi:10.1159/000525092. Cote ML, Ruterbusch JJ, Olson SH, Lu K, Ali-Fehmi R. The growing burden of endometrial cancer: a major racial disparity affecting Black women. Cancer Epidemiol Biomarkers Prev. 2015;24(9):1407-1415. doi:10.1158/1055-9965.epi-15-0316. Vikas P, Messersmith H, Compton C, et al. Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy: ASCO endorsement of College of American Pathologists guideline. J Clin Oncol. 2023;41(10):1943-1948. doi:10.1200/jco.22.02462. |
فهرسة مساهمة: | Keywords: discordant results; endometrial cancer; mismatch repair (MMR); prognostication |
المشرفين على المادة: | 0 (Biomarkers, Tumor) EC 3.6.1.3 (MutL Protein Homolog 1) |
تواريخ الأحداث: | Date Created: 20231030 Date Completed: 20240202 Latest Revision: 20240311 |
رمز التحديث: | 20240312 |
DOI: | 10.1002/cncr.35067 |
PMID: | 37902951 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1097-0142 |
---|---|
DOI: | 10.1002/cncr.35067 |